MX342913B - Formas solidas de romidepsina y sus usos. - Google Patents

Formas solidas de romidepsina y sus usos.

Info

Publication number
MX342913B
MX342913B MX2013000446A MX2013000446A MX342913B MX 342913 B MX342913 B MX 342913B MX 2013000446 A MX2013000446 A MX 2013000446A MX 2013000446 A MX2013000446 A MX 2013000446A MX 342913 B MX342913 B MX 342913B
Authority
MX
Mexico
Prior art keywords
solid forms
present disclosure
disclosure provides
compound
romidepsin
Prior art date
Application number
MX2013000446A
Other languages
English (en)
Other versions
MX2013000446A (es
Inventor
Smolenskaya Valeriya
Vrolijk Nicholas
Hanko Jason
Alan Engers David
Hagen Eric
Scott Stults Jeffrey
Harishchandra Naringrekar Vijay
Tzatchev Peykov Viktor
Rodney Foss Willard
Lawrence Darling Neil
Original Assignee
Celgene Corp *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp * filed Critical Celgene Corp *
Publication of MX2013000446A publication Critical patent/MX2013000446A/es
Publication of MX342913B publication Critical patent/MX342913B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K11/00Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15Depsipeptides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

La presente invención se refiere a formas sólidas de un compuesto que tiene la fórmula I. En algunas modalidades la presente descripción proporciona formas cristalinas del Compuesto I. En algunas modalidades la presente descripción proporciona formas solvatadas del Compuesto I. En algunas modalidades la presente descripción proporciona formas amorfas del Compuesto I.
MX2013000446A 2010-07-12 2011-07-12 Formas solidas de romidepsina y sus usos. MX342913B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36352210P 2010-07-12 2010-07-12
PCT/US2011/043680 WO2012009336A1 (en) 2010-07-12 2011-07-12 Romidepsin solid forms and uses thereof

Publications (2)

Publication Number Publication Date
MX2013000446A MX2013000446A (es) 2013-05-01
MX342913B true MX342913B (es) 2016-10-19

Family

ID=44514993

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000446A MX342913B (es) 2010-07-12 2011-07-12 Formas solidas de romidepsina y sus usos.

Country Status (16)

Country Link
US (5) US20120190817A2 (es)
EP (1) EP2593123B1 (es)
JP (3) JP6049614B2 (es)
KR (1) KR20130092557A (es)
CN (1) CN103108648A (es)
AU (1) AU2011279303B2 (es)
BR (1) BR112013000673A2 (es)
CA (1) CA2804795A1 (es)
ES (1) ES2755909T3 (es)
MX (1) MX342913B (es)
MY (1) MY185130A (es)
NZ (2) NZ706052A (es)
RU (2) RU2016149485A (es)
SG (2) SG10201505475XA (es)
UA (1) UA114074C2 (es)
WO (1) WO2012009336A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007342030B2 (en) * 2006-12-29 2013-08-15 Celgene Corporation Romidepsin-based treatments for cancer
DE102011090178A1 (de) * 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
US20130184225A1 (en) 2012-01-12 2013-07-18 Lianfeng Huang Romidepsin formulations and uses thereof
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
CN103877010B (zh) * 2012-12-21 2018-06-01 正大天晴药业集团股份有限公司 一种罗米地辛溶液的制备方法
WO2014102731A1 (en) * 2012-12-31 2014-07-03 Leiutis Pharmaceuticals Pvt. Ltd Novel pharmaceutical compositions of romidepsin
ITMI20131856A1 (it) * 2013-11-08 2015-05-09 Gnosis Spa Processo per la preparazione di differenti forme cristalline del s-acetil glutatione e loro utilizzi in formulazioni farmaceutiche e nutraceutiche
CN103861084A (zh) * 2014-02-12 2014-06-18 新乡医学院 Romidepsin在治疗帕金森病中的应用
CN104262456B (zh) * 2014-09-11 2018-01-09 浙江海正药业股份有限公司 一种罗米地辛的新晶型及其制备方法和用途
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
EP4049665B1 (en) 2016-03-15 2025-03-12 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
CN105801667B (zh) * 2016-03-22 2019-04-09 浙江海正药业股份有限公司 一种制备无定型罗米地辛的方法
CN110191706A (zh) * 2016-11-22 2019-08-30 阿卡利德公司 治疗利多卡因无效病症和低钾血病症的治疗方法
CN109796521B (zh) * 2017-11-17 2022-04-19 上海医药工业研究院 一种罗米地辛醋酸盐晶型及其制备方法
EA202092684A1 (ru) 2018-08-27 2021-03-11 Ридженерон Фармасьютикалз, Инк. Применение рамановской спектроскопии для последующей очистки
CN111187337B (zh) * 2018-11-15 2023-01-24 上海医药工业研究院 罗米地辛一异丙醇溶剂合物及其晶型、制备方法和应用
WO2020139453A2 (en) * 2018-12-24 2020-07-02 Marrone Bio Innovations, Inc. A method for increasing romidepsin production from fermentation broth
WO2021253338A1 (zh) * 2020-06-18 2021-12-23 中国科学院深圳先进技术研究院 罗米地辛在预防和治疗冠状病毒相关疾病中的应用
CN113813366A (zh) * 2020-06-18 2021-12-21 中国科学院深圳先进技术研究院 罗米地辛在制备预防和治疗抗新冠肺炎新型冠状病毒的药物中的应用

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
JPH0764872A (ja) 1993-08-26 1995-03-10 Fujitsu Ten Ltd データ記憶制御装置
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US5776905A (en) 1996-08-08 1998-07-07 The Board Of Trustees Of The Leland Stamford Junior University Apoptotic regression of intimal vascular lesions
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
JP3494624B2 (ja) 1997-09-02 2004-02-09 住友製薬株式会社 新規な環状テトラペプチド誘導体とその医薬用途
JPH11335375A (ja) 1998-05-20 1999-12-07 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
US6214986B1 (en) 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
US20070148228A1 (en) 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
HUP0202707A3 (en) 1999-09-08 2003-11-28 Univ Columbia Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and pharmaceutical compositions containing them and use thereof
ATE353663T1 (de) 1999-12-08 2007-03-15 Cyclacel Pharmaceuticals Inc Verwendung von depsipeptide und deren analoge als immunosuppressiva zur behandlung von infektionskrankheiten, autoimmunerkrankungen, allergien und hyperproliferativer hautkrankheiten
US6828302B1 (en) 1999-12-08 2004-12-07 Xcyte Therapies, Inc. Therapeutic uses of depsipeptides and congeners thereof
CA2317003A1 (en) 2000-02-28 2001-08-28 Hidenori Nakajima Gene expression potentiator
JP2001348340A (ja) 2000-06-07 2001-12-18 Yamanouchi Pharmaceut Co Ltd ヒストン脱アセチル化酵素阻害剤
US7056884B2 (en) 2000-07-17 2006-06-06 Astellas Pharma Inc. Reduced FK228 and use thereof
WO2002015921A2 (en) * 2000-08-18 2002-02-28 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
AU2001280109A1 (en) * 2000-09-01 2002-03-22 Fujisawa Pharmaceutical Co. Ltd. A method of producing fr901228
AU2002243231A1 (en) 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
WO2002055688A2 (en) 2001-01-10 2002-07-18 Us Gov Health & Human Serv Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
ES2310213T3 (es) 2001-05-02 2009-01-01 The Regents Of The University Of California Procedimiento para tratar trastornos neurodegenerativos, psiquiatricos y otros trastornos con inhibidores de desacetilasa.
WO2002097053A2 (en) 2001-05-30 2002-12-05 The Regents Of The University Of Michigan Small molecule antagonists of bcl2 family proteins
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
PT1426054E (pt) 2001-08-21 2011-12-06 Astellas Pharma Inc Utilização medicinal de inibidor da histona desacetilase e método de avaliação do seu efeito antitumoral
WO2003017763A1 (en) 2001-08-24 2003-03-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of a histone deacetylase inhibitor to increase the entry of an adenoviral agent into a cell
EP1293205A1 (en) 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
US20050123896A1 (en) 2001-10-25 2005-06-09 Benz Christopher C. Screening system for modulators of her2 mediated transcription and her2 modulators identified thereby
US7354928B2 (en) 2001-11-01 2008-04-08 The Regents Of The University Of Michigan Small molecule inhibitors targeted at Bcl-2
WO2003053468A1 (en) 2001-12-21 2003-07-03 Universite Libre De Bruxelles Method for obtaining the elimination of integrated and functional viruses from infected mammal cells
US20030134423A1 (en) 2002-01-04 2003-07-17 Chu Yong Liang Compounds for delivering substances into cells
AU2003219803B8 (en) 2002-02-15 2005-08-25 Sloan-Kettering Institute For Cancer Research Method of treating TRX mediated diseases
WO2003070754A1 (fr) 2002-02-20 2003-08-28 Minoru Yoshida Inhibiteurs d'histone desacetylase et procede de production de ces inhibiteurs
NZ550185A (en) 2002-03-04 2008-10-31 Merck Hdac Res Llc Methods of inducing terminal differentiation Methods of inducing terminal differentiation
US20040077591A1 (en) 2002-03-28 2004-04-22 The Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease
MXPA04009761A (es) 2002-04-05 2005-05-27 Fujisawa Pharmaceutical Co Dipsipeptido para terapia de cancer renal.
AU2003226408B2 (en) 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
US6809118B2 (en) 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US20040002447A1 (en) 2002-06-04 2004-01-01 Regents Of The University Of California Induction of insulin expression
US20050065596A1 (en) 2002-07-24 2005-03-24 Xufan Tseng Stents capable of controllably releasing histone deacetylase inhibitors
DE60332367D1 (de) 2002-08-20 2010-06-10 Astellas Pharma Inc Hemmer des abbaus der extrazellulären matrix von arthrodia-knorpel
CN1681505A (zh) 2002-09-13 2005-10-12 弗吉尼亚州立大学 用于治疗白血病的а ) N-{ 5-[ 4-( 4-甲基-哌嗪-1-基-甲基)-苯甲酰氨基]-2-甲基苯基}-4-( 3-吡啶基 ) -2-嘧啶-胺和b )组蛋白脱乙酰基酶抑制剂的组合
SE0300098D0 (sv) 2003-01-15 2003-01-15 Forskarpatent I Syd Ab Use of cyclin D1 inhibitors
US20050222013A1 (en) 2003-01-16 2005-10-06 Georgetown University Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy
CA2519320A1 (en) 2003-02-19 2004-09-02 Astellas Pharma Inc. Method of estimating antitumor effect of histone deacetylase inhibitor
JP4588634B2 (ja) 2003-04-25 2010-12-01 尚巳 岡田 遺伝子導入効率増強剤および商業的パッケージ
US20040213826A1 (en) 2003-04-28 2004-10-28 Marx Steven O. Medical devices and methods for inhibiting proliferation of smooth muscle cells
EP1491188A1 (en) 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
WO2005000332A2 (en) 2003-06-27 2005-01-06 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
PL379887A1 (pl) 2003-08-26 2006-11-27 Merck Hdac Research, Llc Sposób leczenia raka inhibitorami HDAC
US20070190022A1 (en) 2003-08-29 2007-08-16 Bacopoulos Nicholas G Combination methods of treating cancer
US20050059682A1 (en) 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
CA2538570A1 (en) 2003-09-18 2005-03-31 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
SI2263694T1 (sl) * 2003-09-25 2013-09-30 Astellas Pharma Inc. Antitumorsko sredstvo, ki obsega inhibitor histon-deacetilaze FK228 in inhibitor topoizomeraze II doksorubicin
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
WO2005052143A2 (de) 2003-11-14 2005-06-09 Per Sonne Holm Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
CA2546178A1 (en) 2003-11-14 2005-06-09 Per Sonne Holm New use of adenovirus and nucleic acids coding therefor
WO2005053609A2 (en) 2003-11-26 2005-06-16 Guilford Pharmaceuticals Inc. Methods of nad+-dependent deacetylase inhibitors
WO2005058298A2 (en) 2003-12-10 2005-06-30 Wisconsin Alumni Research Foundation Fk228 analogs and their use as hdac-inhibitors
US20050187148A1 (en) 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
ATE437370T1 (de) 2004-02-27 2009-08-15 Us Gov Health & Human Serv Pharmakodynamische tests mit durchflusszytometrie
GB0405349D0 (en) 2004-03-10 2004-04-21 Univ Birmingham Cancer therapy and medicaments therefor
ITMI20040876A1 (it) 2004-04-30 2004-07-30 Univ Degli Studi Milano Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
EP1591109B1 (en) 2004-04-30 2008-07-02 TopoTarget Germany AG Formulation comprising histone deacetylase inhibitor exhibiting biphasic release
WO2005115149A2 (en) 2004-05-20 2005-12-08 Dow Agrosciences Llc Insectidal activity of a cyclic peptide
WO2005117930A2 (en) 2004-06-04 2005-12-15 Sloan-Kettering Institute For Cancer Research Use of thioredoxin measurements for diagnostics and treatments
WO2005123089A2 (en) 2004-06-10 2005-12-29 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
US20060018921A1 (en) 2004-07-16 2006-01-26 Baylor College Of Medicine Histone deacetylase inhibitors and cognitive applications
US7745446B2 (en) 2004-09-06 2010-06-29 Bayer Schering Pharma Aktiengesellschaft Pyrazolo[1,5-c]pyrimidines
AU2005307814A1 (en) 2004-11-17 2006-05-26 The University Of Chicago Histone deacetylase inhibitors and methods of use
US8889742B2 (en) 2004-11-30 2014-11-18 The Trustees Of The University Of Pennsylvania Use of HDAC and/or DNMT inhibitors for treatment of ischemic injury
WO2006060429A2 (en) 2004-12-03 2006-06-08 Novartis Ag Identification of variants in histone deacetylase 1 (hdac1) to predict drug response
US20060128660A1 (en) 2004-12-10 2006-06-15 Wisconsin Alumni Research Foundation FK228 analogs and methods of making and using the same
GB0511266D0 (en) 2005-06-02 2005-07-13 Trust Chemical compounds
EP1743654A1 (en) 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
WO2007040522A1 (en) 2005-09-30 2007-04-12 The Ohio State Research Foundation Antitumor agents
WO2007049736A1 (ja) * 2005-10-28 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. 濃縮晶析装置および方法
EP1957673A2 (en) 2005-11-10 2008-08-20 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Materials and methods for abcb1 polymorphic variant screening, diagnosis, and treatment
AU2006318652A1 (en) 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Metabolite derivatives of the HDAC inhibitor FK228
WO2007145704A2 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
CA2654566A1 (en) 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7857804B2 (en) 2006-09-01 2010-12-28 Mccaffrey Timothy A Use of Bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders
AU2007342030B2 (en) 2006-12-29 2013-08-15 Celgene Corporation Romidepsin-based treatments for cancer
CN107090482A (zh) * 2006-12-29 2017-08-25 细胞基因公司 制备Romidepsin
CN102276689A (zh) 2011-05-09 2011-12-14 中国药科大学 组蛋白去乙酰化酶抑制剂fk228的化学合成方法及其应用

Also Published As

Publication number Publication date
JP2019052177A (ja) 2019-04-04
EP2593123B1 (en) 2019-09-04
RU2607634C2 (ru) 2017-01-10
NZ605526A (en) 2015-04-24
US20160060300A1 (en) 2016-03-03
BR112013000673A2 (pt) 2016-05-31
KR20130092557A (ko) 2013-08-20
SG10201505475XA (en) 2015-09-29
CA2804795A1 (en) 2012-01-19
JP2013532632A (ja) 2013-08-19
JP2017008067A (ja) 2017-01-12
US20150218225A1 (en) 2015-08-06
JP6049614B2 (ja) 2016-12-21
EP2593123A1 (en) 2013-05-22
US8980825B2 (en) 2015-03-17
US20140256637A1 (en) 2014-09-11
WO2012009336A1 (en) 2012-01-19
MX2013000446A (es) 2013-05-01
US20140336132A1 (en) 2014-11-13
CN103108648A (zh) 2013-05-15
RU2013105700A (ru) 2014-08-20
US20120046442A1 (en) 2012-02-23
US9624271B2 (en) 2017-04-18
NZ706052A (en) 2016-07-29
US20120190817A2 (en) 2012-07-26
RU2016149485A (ru) 2018-10-31
JP6490632B2 (ja) 2019-03-27
AU2011279303B2 (en) 2015-07-16
SG187032A1 (en) 2013-02-28
AU2011279303A1 (en) 2013-01-31
UA114074C2 (xx) 2017-04-25
US9518094B2 (en) 2016-12-13
MY185130A (en) 2021-04-30
ES2755909T3 (es) 2020-04-24

Similar Documents

Publication Publication Date Title
MX2013000446A (es) Formas solidas de romdepsina y sus usos.
PH12017502300A1 (en) Pesticidal compositions and processes related thereto
MX341133B (es) Compuestos y metodos para la inhibición de hdac.
GB201001075D0 (en) Crystalline forms
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
MX2012008141A (es) Compuestos y metodos.
IN2012DN04748A (es)
EP2415049A4 (en) Negative voltage generation
IN2012DN04414A (es)
PL2578595T3 (pl) Krystaliczna lewoizowalerylospiramycyna I
IL219243A0 (en) 5-hydroxyprimidine-4-carboxamide derivatives, compositions comprising the same and uses threof
IN2012DN04412A (es)
EP2650330A4 (en) Epdm composition
AU2011298391A8 (en) Substituted N-phenethyltriazoloneacetamides and uses thereof
HK1184739A (en) Romidepsin solid forms and uses thereof
IN2012DN04805A (es)
GB0805670D0 (en) Increasing the plasticity of stem cells
UA41922U (ru) Применение альтана как вещества с противолучевыми свойствами
UA56041U (ru) 1,3-диметил-7-n-метилбензил-8-гидразиноксантин, который проявляет диуретическое действие
AU2010900738A0 (en) Foliar nutrient compositions
AU2010903712A0 (en) Tutoring Tool
HK1183887A (en) Crystalline ezatiostat hydrochloride ansolvate
IL222981A0 (en) Compound, synthesis, composition and uses thereof
UA27272U (en) Use of yakton as cardioprotector
UA41660U (en) Use of jacton and mexidol as actoprotector

Legal Events

Date Code Title Description
FG Grant or registration